HBsAg quantification in prediction of the long-term efficacy of interferon for chronic hepatitis B
10.3969/j.issn.1006-5725.2015.07.009
- VernacularTitle:HBsAg定量检测对干扰素治疗慢性乙型肝炎远期疗效的预测价值
- Author:
Yang YANG
;
Long YANG
;
Xuehua JIANG
;
Zhiyong CHEN
- Publication Type:Journal Article
- Keywords:
Hepatitis B,chronic;
Hepatitis B surface antigen;
Interferon;
Quantification;
Prediction
- From:
The Journal of Practical Medicine
2015;(7):1068-1071
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of serum HBsAg quantification in prediction of interferon treatment of HBeAg-positive chronic hepatitis B (CHB). Methods 75 patients with HBeAg-positive CHB received peginterferon alfa-2a (PegIFNα-2a) at a dose of 180 μg weekly for 48 weeks with 24 weeks of a pose-treatment follow-up. Serum HBsAg quantification and level of HBV DNA were measured during the treatment and the pose-treatment follow-up. Results In the post-treatment follow-up , the patients were divided into sustained response (SR) group, relapse group, and non-response group. Serum level of HBV DNA did not differ significantly between SR group and relapse group , but was lower than that in non-response group. However , there was no significant difference in HBsAg quantification between relapse group and non-response group , but the level of quantification was higher in both group than in SR group. Serum HBsAg declined more than 1 log10 IU/mL at week 12 , with sensitivity , specificity , and positive and negative predictive value of 86%, 94%, 95%and 94%. The accuracy of the cut-off with a 1 log10 IU/mL decrease in HBsAg level at week 12 of PegIFNα-2a therapy to predict SVR was assessed using receiver operating characteristic curve , and the area under the curve was 0.952. Conclusion The change in serum HBV DNA level could not predict SR effectively, but serum HBsAg quantification is an ideal parameter for predicting the efficacy of interferon therapy.
